Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-07-863241
Abstract: TO THE EDITOR: Waldenstrom macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with immunoglobulin M monoclonal gammopathy.[1][1] The majority of patients carry the L265P mutation in MYD88,[2][2] whereas 40% of patients carry mutations in CXCR4.[3][3]… read more here.
Keywords: impact cxcr4; negative impact; macroglobulinemia; waldenstrom macroglobulinemia ... See more keywords